DuRvalumab with chEmotherapy as first line treAtment in advanced pleural Mesothelioma: A phase 3 randomised trial. The DREAM3R trial

被引：0
|
作者：
John, Thomas [1 ]
Forde, Patrick [2 ]
Kok, Peey Sei [3 ]
Brown, Chris [3 ]
Sun, Zhuoxin [4 ]
O'Byrne, Kenneth [5 ,6 ]
Yip, Sonia [3 ]
Anagnostou, Valasamo [7 ]
Cook, Alistair [8 ,9 ]
Lesterhuis, Willem J. [8 ]
Hughes, Brett G. M. [10 ,11 ]
Johnson, Lisa [12 ]
Oostendorp, Martijn [3 ]
Marinucci, Donna [12 ]
Fitzpatrick, Karen [12 ]
Ford, Kate [3 ]
Pavlakis, Nick [13 ,14 ]
Brahmer, Julie [2 ]
Stockler, Martin R. [3 ]
Ramalingam, Suresh [15 ]
Nowak, Anna [8 ,9 ,16 ]
机构：
[1] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[2] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Sydney, Nhmrc Clin Trials Ctr, Camperdown, NSW, Australia
[4] IBCSG Stat Ctr, Boston, MA USA
[5] Princess Alexandra Hosp, Brisbane, Qld, Australia
[6] Queensland Univ Technol, Brisbane, Qld, Australia
[7] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[8] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia
[9] Univ Western Australia, Med Sch, Perth, WA, Australia
[10] Prince Charles Hosp, Canc Care Serv, Brisbane, Qld, Australia
[11] Univ Queensland, Brisbane, Qld, Australia
[12] PrECOG, Philadelphia, PA USA
[13] Northern Canc Inst, Sydney, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[16] Sir Charles Gairdner Hosp, Med Oncol, Perth, WA, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
404
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [31] UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
    Haakensen, Vilde Drageset
    Ojlert, Asa Kristina
    Thunold, Solfrid
    Farooqi, Saima
    Nowak, Anna K.
    Chin, Wee L.
    Grundberg, Oscar
    Szejniuk, Weronika Maria
    Cedres, Susana
    Sorensen, Jens Benn
    Dalen, Tonje Sofie
    Lund-Iversen, Marius
    Bjaanaes, Maria
    Helland, Aslaug
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [32] Tumor Treating Fields plus chemotherapy for first-line treatment of malignant pleural mesothelioma: Final Results of the STELLAR Trial
    Ceresoli, G.
    Aerts, J.
    Madrzak, J.
    Dziadziuszko, R.
    Ramlau, R.
    Cedres, S.
    Hiddinga, B.
    Van Meerbeeck, J. P.
    Mencoboni, M.
    Planchard, D.
    Chella, A.
    Krzakowski, M.
    Crino, L.
    Grosso, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 230 - 231
  • [33] Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma - A phase II FONICAP trial
    Pennucci, MC
    Ardizzoni, A
    Pronzato, P
    Fioretti, M
    Lanfranco, C
    Verna, A
    Giorgi, G
    Vigani, A
    Frola, C
    Rosso, R
    CANCER, 1997, 79 (10) : 1897 - 1902
  • [34] A phase II trial of paclitaxel (Taxol(R)) as first line treatment in advanced breast cancer
    Swain, SM
    Honig, SF
    Tefft, MC
    Walton, L
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 217 - 222
  • [35] A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
    Fujimoto, Nobukazu
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Oze, Isao
    Kato, Katsuya
    Kishimoto, Takumi
    Hotta, Katsuyuki
    CLINICAL LUNG CANCER, 2018, 19 (05) : E705 - E707
  • [36] Cetuximab plus platinum-based chemotherapy in patients with malignant pleural mesothelioma: A single arm phase II trial.
    De Paepe, Annelies
    Vermaelen, Karim Y.
    Cornelissen, Robin
    Germonpre, Paul Richard
    Janssens, Annelies
    Lambrechts, Marc
    Bootsma, Gerben
    Van Meerbeeck, Jan P.
    Surmont, Veerle
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Radiological Response Patterns in Malignant Pleural Mesothelioma (MPM): Subgroup Analyses of the Phase 2 Stellar Trial of TTFields Plus Chemotherapy for First-Line Treatment
    Grosso, F.
    Ceresoli, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S147 - S148
  • [38] 3-day topotecan and carboplatin in first line treatment of optimally debulked ovarian cancer: A phase II trial.
    Estape, R
    Estape, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 490S - 490S
  • [39] Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial
    Tingyan Shi
    Rong Jiang
    Jinjin Yu
    Huijuan Yang
    Dongsheng Tu
    Zhiyuan Dai
    Yang Shen
    Yuqin Zhang
    Xi Cheng
    Huixun Jia
    Ruiqin Tu
    Huaying Wang
    Jie Tang
    Yuting Luan
    Shumo Cai
    Rongyu Zang
    British Journal of Cancer, 2018, 119 : 12 - 18
  • [40] Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial
    Shi, Tingyan
    Jiang, Rong
    Yu, Jinjin
    Yang, Huijuan
    Tu, Dongsheng
    Dai, Zhiyuan
    Shen, Yang
    Zhang, Yuqin
    Cheng, Xi
    Jia, Huixun
    Tu, Ruiqin
    Wang, Huaying
    Tang, Jie
    Luan, Yuting
    Cai, Shumo
    Zang, Rongyu
    BRITISH JOURNAL OF CANCER, 2018, 119 (01) : 12 - 18
12345